Clinical Trial Search

Primary: Change From Baseline Trough in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) on Treatment Day 84 — 0.168; 0.142 Liters — p=0.137

Primary: Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (KM-YBOCS) — 5.4 units on a scale

Primary: CHADS2 Score — 102; 386; 575 participants

Primary: Number of Participants With BRAF V600E Mutation-positive Melanoma With Overall Intracranial Response (OIR), as Assessed by the Investigator — 4; 1; 26; 23 participants…

Primary: Percentage of Patients Who Have at Least a 50% Reduction (i.e., Success) in at Least 1 of the First 12 Chemotherapy Induced Peripheral Neuropathy (CIPN) Measurement…

Primary: Number of Participants With Wound Healing — 10 participants

Primary: Shear Rheology — 6.0; 1.8 Pascal

Primary: Comparison of Postoperative Nausea and Vomiting Scores Between Groups Treated With a ReletexTM Device and Those Without the Device. — 1.81; 2.03 units on a scale

Primary: Lens Fit Acceptance — 158; 158; 157; 0 eyes

Primary: Percentage of Participants With Giant Cell Tumor Response — 85.7 percentage of participants

Primary: Overall Objective Response — 4; 18; 2; 1 participants

Primary: The Taste Score for the Last Dose of the Suspension on Day 3 for Subjects 5 - <18 Years — 4.0 units on a scale

Primary: Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg) — 110.97 Ratio

Primary: Safety and Tolerability - Number of Participants With Treatment Emergent Adverse Events (TEAEs = Adverse Events That Started During or After the First Dose of Study…

Primary: International Knee Documentation Committee (IKDC) Form — 89; 88 score